Biosimilar Rutiximabs, and Inotuzumab, Coming to Europe Biosimilar Rutiximabs, and Inotuzumab, Coming to Europe
Two biosimilar rituximab products have been recommended for approval in Europe, as has inotuzumab ozogamicin for acute lymphoblastic leukemia.International Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 24, 2017 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
He lost his sight to cancer, but not his vision of a full life
When Tim Conners collected his wish from the Make-A-Wish Foundation in 2012 at the age of 18, he was blind from childhood leukemia that had spread to his optic nerve and craving inspiration to transcend his disability. A football player and wrestler who’d never been an outdoorsman, he asked to meet Erik Weihenmayer, the first blind person to climb the Seven Summits, the highest mountains on seven continents.
Tim’s wish came true. He had 2½ terrifying but transformative days of outdoor adventures in Colorado with Erik, who lost his sight to a degenerative eye disorder at 13.
Now Tim is training to climb Mount Kili...
Source: Thrive, Children's Hospital Boston - April 20, 2017 Category: Pediatrics Authors: Irene Sege Tags: Diseases & Conditions Our Patients’ Stories acute lymphoblastic leukemia (ALL) Dana-Farber/Boston Children's Cancer and Blood Disorders Center stem cell transplant Source Type: news
Blinatumomab Active in Ph+ B-Precursor Acute Lymphoblastic Leukemia
Single-agent use of blinatumomab resulted in anti-leukemic activity in patients with tyrosine kinase inhibitor –relapsed or refractory Philadelphia chromosome positive B-precursor acute lymphoblastic leukemia. (Source: CancerNetwork)
Source: CancerNetwork - April 19, 2017 Category: Cancer & Oncology Tags: Hematologic Malignancies Leukemia & Lymphoma News Source Type: news
Erytech begins Phase II trial of eryaspase to treat ALL
French biopharmaceutical firm Erytech Pharma has begun a Phase II clinical trial of eryaspase (GRASPA) for the treatment of patients with acute lymphoblastic leukaemia (ALL). (Source: Drug Development Technology)
Source: Drug Development Technology - April 4, 2017 Category: Pharmaceuticals Source Type: news
Low Disease Burden Improved Durability of CAR T-Cell Therapy in B-ALL
Low pretreatment disease burden improved durability of CAR T-cell therapy in patients with relapsed B-cell acute lymphoblastic leukemia. (Source: CancerNetwork)
Source: CancerNetwork - April 4, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Leukemia & Lymphoma News Source Type: news
Novartis says U.S. regulator grants speedy review of CAR-T cell therapy
ZURICH (Reuters) - Novartis AG on Wednesday said the U.S. Food and Drug Administration (FDA) has agreed to accelerate its review of the Swiss drugmaker's CTL019 therapy for young patients with B-cell acute lymphoblastic leukemia. (Source: Reuters: Health)
Source: Reuters: Health - March 30, 2017 Category: Consumer Health News Tags: healthNews Source Type: news
An epigenetic lesion could be responsible for acute T-cell leukemia
(IDIBELL-Bellvitge Biomedical Research Institute) Researchers from the Epigenetics and Cancer Biology Program (PEBC) led by Dr. Manel Esteller at IDIBELL have discovered how an epigenetic lesion can lead to T-cell acute lymphoblastic leukemia. The article, published in the journal Leukemia, correlates the lesion with the activation of a powerful oncogen capable of malignizing this type of cells of the immune system. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 30, 2017 Category: Global & Universal Source Type: news
FDA Grants Priority Review For Amgen's BLINCYTO ® (blinatumomab) Supplemental Biologics License Application
Application Includes Overall Survival Data From Phase 3 TOWER Study to Support Conversion From Accelerated Approval to Full Approval
Acceptance Reinforces Significant Need for Innovative Treatment Options for Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
BLINCYTO is the First-and-Only Approved Bispecific CD19-Directed CD3 T Cell Engager (BiTE®) Immunotherapy
THOUSAND OAKS, Calif., March 29, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the supplemental Biologics License Application (sBLA) for BLINCYTOÂ...
Source: Amgen News Release - March 29, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Journal Of Clinical Oncology Publishes Data On BLINCYTO ® (Blinatumomab) In High-Risk Patients With Philadelphia Chromosome-Positive B-Cell Precursor Acute Lymphoblastic Leukemia
BLINCYTO is the Only Bispecific T Cell Engager (BiTE®) Immunotherapy Approved in the U.S.
Complete Remission or Complete Remission With Partial Hematologic Recovery was Induced in More Than 35 Percent of Patients
THOUSAND OAKS, Calif., March 29, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Journal of Clinical Oncology published results from the Phase 2, open-label ALCANTARA study evaluating the efficacy and safety of BLINCYTO® (blinatumomab) in patients with Philadelphia chromosome-positive (Ph+) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) who had failed at leas...
Source: Amgen News Release - March 29, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
C-Section and Risk of Childhood Acute Lymphoblastic Leukemia C-Section and Risk of Childhood Acute Lymphoblastic Leukemia
This study suggests that delivery by elective C-section is associated with a higher risk of childhood acute lymphoblastic leukemia. What might be the etiology?American Journal of Epidemiology (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - March 9, 2017 Category: Allergy & Immunology Tags: Pediatrics Journal Article Source Type: news
BLINCYTO(R) (blinatumomab) Significantly Improved Overall Survival In Patients With B-Cell Precursor Acute Lymphoblastic Leukemia Compared To Chemotherapy
THOUSAND OAKS, Calif., March 1, 2017 -- (Healthcare Sales & Marketing Network) -- Amgen (AMGN) today announced the New England Journal of Medicine published results from the Phase 3 TOWER study evaluating the efficacy of BLINCYTO® (blinatumomab) versu... Biopharmaceuticals, Oncology Amgen, BLINCYTO, blinatumomab, acute lymphoblastic leukemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 2, 2017 Category: Pharmaceuticals Source Type: news
Juno ends flagship drug trial after deaths and FDA suspensions
Juno Therapeutics has ended its flagship cancer drug trial that the Food and Drug Administration suspended in November after patient deaths.
The Phase II "Rocket" trial used Juno’s JCAR015 immunotherapy treatment to re-engineer adult patients’ immune systems to fight acute lymphoblastic leukemia (ALL).
The FDA suspended the same trial in July after two patients died from cerebral edema, or swelling in the brain that is the result of excessive fluid buildup. A fifth patient died in May from… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - March 1, 2017 Category: American Health Authors: Casey Coombs Source Type: news
Juno ends flagship drug trial after deaths and FDA suspensions
Juno Therapeutics has ended its flagship cancer drug trial that the Food and Drug Administration suspended in November after patient deaths.
The Phase II "Rocket" trial used Juno’s JCAR015 immunotherapy treatment to re-engineer adult patients’ immune systems to fight acute lymphoblastic leukemia (ALL).
The FDA suspended the same trial in July after two patients died from cerebral edema, or swelling in the brain that is the result of excessive fluid buildup. A fifth patient died in May from… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - March 1, 2017 Category: Biotechnology Authors: Casey Coombs Source Type: news
BLINCYTO ® (blinatumomab) Significantly Improved Overall Survival In Patients With B-Cell Precursor Acute Lymphoblastic Leukemia Compared To Chemotherapy
BLINCYTO Almost Doubled Median Overall Survival in High-Risk Patients With B-Cell Precursor Acute Lymphoblastic Leukemia Compared to Standard of Care Chemotherapy
BLINCYTO is the First-and-Only Bispecific CD19-Directed CD3 T Cell Engager (BiTE®) Immunotherapy to Demonstrate Overall Survival Benefit in Patients With Philadelphia Chromosome-Negative Relapsed or Refractory Acute Lymphoblastic Leukemia
Results Published in The New England Journal of Medicine
THOUSAND OAKS, Calif., March 1, 2017 /PRNewswire/ --Â Amgen (NASDAQ:AMGN) today announced the New England Journal of Medicine published results from the Phase 3 ...
Source: Amgen News Release - March 1, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
